News | December 23, 2021
Evusheld neutralises Omicron in latest studies
Only antibody authorised in the US for pre-exposure prophylaxis of COVID-19
Only antibody authorised in the US for pre-exposure prophylaxis of COVID-19
The 50,000 square foot expansion will house a high-speed filling line and lyophilizers, which will increase the facility’s sterile injectable capacity by 50%
The vaccine is designed to neutralise the virus in the nostril itself and prevent it from penetrating deep down into the respiratory tract
Advance to Phase 3 follows positive interim Phase 1/2 immunogenicity and safety data. The global clinical trial will evaluate vaccine candidate GBP510 against the AZ/Oxford COVID-19 vaccine
Opaganib, a leading novel small molecule investigational oral pill in development for Covid-19, is a unique host targeted, dual antiviral and anti-inflammatory drug that acts on the cause and effect of the disease
This is the first of its kind vaccine for Covid 19 to get the go-ahead
This investment is being made to set up a high speed 400 vials a minute injectable fill line with isolator technology
Jubilant successfully challenged Bracco's patent infringement claims in an Inter Parties Review (IPR) proceeding before the U.S. Patent Office
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
